LIPITOR Drug Patent Profile

When do Lipitor patents expire, and what generic alternatives are available?

Lipitor is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in LIPITOR is atorvastatin calcium. There are sixty-two drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lipitor

A generic version of LIPITOR was approved as atorvastatin calcium by APOTEX INC on May 29^th, 2012.

Summary for LIPITOR

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LIPITOR

US Patents and Regulatory Information for LIPITOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-001	Dec 17, 1996	AB	RX	Yes	No
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-004	Apr 7, 2000	AB	RX	Yes	Yes
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-002	Dec 17, 1996	AB	RX	Yes	No
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-003	Dec 17, 1996	AB	RX	Yes	No

International Patents for LIPITOR

See the table below for patents covering LIPITOR around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2014051533	PROCESS FOR PREPARATION OF CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID (ATORVASTATIN)
Hong Kong	119493	TRANS-6-(2-(3-OR 4-CARBOXAMIDO-SUBSTITUTED PYRROL-1-YL)-ALKYL)-4-HYDROXYPYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS
Estonia	03606	Kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hept aanhappehemikaltsiumsool (atorvastatiin)
Japan	3254219
Peru	1898	ACIDO CRISTALINO [R-(R ,R )]-2-(4-FLUOROFENIL)-�-�-DIHIDROXI-5-(1-METILETIL)-3-FENIL-4-[(FENILAMINO) CARBONIL]-1H-PIRROL-1-HEPTANOICO SAL DE CALCIO(2:1)
South Korea	940001006

Supplementary Protection Certificates for LIPITOR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	92545	Luxembourg		PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
0720599	122014000088	Germany		PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT ATORVASTATIN ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE ATORVASTATIN ALS ATORVASTATINCALCIUMTRIHYDRAT; NAT. REGISTRATION NO/DATE: 90223.00.00 20141113; FIRST REGISTRATION: FRANKREICH CIS: 6 928 917 6 20140912
0247633	9790036	Sweden		PRODUCT NAME: ATORVASTIN OCH FARMACEUTISKT GODTAGBARA SALTER DäRAV; NAT. REGISTRATION NO/DATE: 13415 19970417; FIRST REG.: GB PL00018/0240 19961107
1003503	05C0048	France		PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
0247633	97C0118	France		PRODUCT NAME: ATORVASTATINE CALCIQUE TRIHYDRATE; REGISTRATION NO/DATE IN FRANCE: NL 21960 DU 19970321; REGISTRATION NO/DATE AT EEC: PL 00018/0240 DU 19961107
0247633	97C0103	Belgium		PRODUCT NAME: CALCII ATORVASTATINUM TRIHYDRICUM (=ATORVASTATINUM); NAT. REGISTRATION NO/DATE: 19 IS 95 F 3 19970922; FIRST REGISTRATION: GB PL/00018/0240 19961107

LIPITOR (Atorvastatin): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Lipitor (generic name: atorvastatin) remains one of the most significant pharmaceuticals in the cardiovascular therapeutic area despite patent expiry in 2011. This analysis evaluates the current and future investment landscape for Lipitor, examining market dynamics, revenue streams, competitive factors, regulatory environment, and outlook for stakeholders. Key insights suggest that while Lipitor’s patent expiration substantially diminished its exclusivity, evolving market trends—such as LDL cholesterol management, emerging competitors, and generics—shape its ongoing financial trajectory.

Overview of Lipitor: Historical Context and Market Significance

Attribute	Details
Initial Approval	November 1996 by FDA
Patent Expiry	June 2011 (U.S.)
Peak Sales (2006)	$12.9 billion (globally) (source: IMS Health)
Original Market Position	Best-selling drug worldwide pre-patent expiry
Current Status	Generic availability; extensive off-patent market

Lipitor pioneered the statin class and marked a paradigm shift in hyperlipidemia management, contributing over $130 billion in cumulative revenues during its patent-protected period.

Market Dynamics Post-Patent Expiry

Generic Competition and Market Share

Period	Market Share of Lipitor	Impact
Pre-2011	>70% of statin prescriptions	Monopoly position
Post-2011	Rapid generic entry; >90% market share decline	Market erosion for Pfizer
2022	Approx. 10% market share in branded statins	Generics dominate due to price competition

Key Point: The entry of multiple generics (e.g., Teva, Mylan, Sandoz) caused a steep decline in Lipitor’s revenue, prompting Pfizer to pivot towards biosimilars and newer drugs within cardiovascular pharmacotherapy.

Market Size and Trends

Segment	2006	2022	CAGR (2006-2022)
Global Statin Market	$11.2 billion	$23.8 billion	4.5%
Lipitor Share (Branded)	>$12 billion	<$1 billion	-94% due to generics

Drivers of Market Growth:

• Rising prevalence of hyperlipidemia and cardiovascular disease (CVD)
• Increased screening and awareness
• Favorable shifts in guidelines leading to higher statin prescription rates

Challenges:

• Patent expirations reducing profitability
• Price erosion due to generics
• Competition from PCSK9 inhibitors and novel lipid-lowering agents

Financial Trajectory and Revenue Analysis

Revenue Decline Pattern

Year	Lipitor Revenue (U.S.)	Global Revenue	Notes
2011	$7.7 billion	$12.1 billion	Patent expiry begins
2015	$1.8 billion	$2.3 billion	Continued decline
2020	<$500 million	<$900 million	Off-patent dominance

Note: The steep decline illustrates generic erosion, with current revenues primarily from residual prescribing, brand loyalty, and developed markets.

Revenue Projections (Next 5-10 Years)

Scenario	Assumptions	Projected Revenue	Source
Conservative (Status Quo)	Continued generic decline, no new formulations	$200–$300 million/year	Market analytics
Optimistic (New Formulations/Indications)	Introduction of novel indications or formulations	$400–$600 million/year	Market potential

Key Revenue Streams

Source	Current Contributions	Derivative Opportunities
Generic prescribing	Major	Expansion through patent extensions (e.g., formulations)
Hypertension/patient adherence	Moderate	Co-formulations and fixed-dose combinations
Brand loyalty in select markets	Low	Brand revival strategies

Competitive Landscape and Market Share Dynamics

Major Competitors

Drug/Class	Market Share (2022)	Features	Status
Simvastatin, Pravastatin	~25%	Established, less potent	Compete with Lipitor in lower-risk populations
Rosuvastatin (Crestor)	~30%	More potent, higher cost	Growing share; patent expired in 2016, now generic
PCSK9 inhibitors (e.g., Repatha, Praluent)	<5%	Injectable, high cost	Used in high-risk patients, complement statins
Evolocumab, Alirocumab	Growing	Biologics targeting LDL clearance	Future growth alongside statins

Market Share Shift Highlights

Period	Lipitor Market Share	Key Drivers
Pre-2011	>70%	Monopoly, patents
Post-2011	Drop to <10%	Generics, alternative therapies
2020+	Stabilized at <5%	Niche markets, residual prescribing

Regulatory and Policy Impacts

FDA and Global Regulatory Environment

Policy Area	Impact	Details
Patent Laws	Patent cliff	Facilitates generic entry post-expiry
Price Controls	Market pressure	Especially relevant in EU, UK, and emerging markets
Indication Expansion	Market growth	Regulatory approvals for indications like familial hypercholesterolemia
Biosimilars	Competition	Increased approval of biosimilar lipid-lowering agents

Healthcare Policy Trends

• Emphasis on cost-effective therapies
• Increased adoption of generic medications
• Potential restrictions on high-cost biologics and novel agents

Comparison with Similar Drugs and Market Entry Strategies

Parameter	Lipitor (Atorvastatin)	Crestor (Rosuvastatin)	Livalo (Pitavastatin)	Biosimilars (e.g., Repatha biosimilars)
Patent Status	Expired (2011)	Expired (2016)	Active	Approved in some markets
Market Share (2022)	~5% (residual)	~15%	Niche	Growing in some regions
Pricing	Low (generic)	Moderate	High (brand in some markets)	Lower (biosimilar)
Regulatory Approvals	U.S., EU, ROW	U.S., EU, ROW	U.S., EU	Globally diverse

Future Outlook and Growth Opportunities

Growth Driver	Details	Potential Impact
New indications	Familial hypercholesterolemia, prevention	Upward revenue revision
Fixed-dose combinations	Lipitor + other agents	Improved adherence, new market segments
Differentiated formulations	Extended-release or combo drugs	Patent strategies or lifecycle extension
Geographic Expansion	Emerging markets	Untapped revenue streams
Strategic Partnerships	Licensing, co-markets	Market penetration

Deep Dive: Investment Risks and Opportunities

Risks	Details
Patent expiration	Loss of exclusivity, revenue erosion
Competitive biologics	Potential replacement in certain indications
Regulatory changes	Cost-cutting scrutiny, pricing policies
Market saturation	Limited growth in mature markets
Innovation lag	Need for formulation and indication expansion

Opportunities	Details
Lifecycle management	Reformulations, delivery methods
Niches and rare indications	Prescriptions for familial hypercholesterolemia
Biosimilar adoption	Cost-effective alternatives
Digital health integration	Monitoring adherence, remote prescribing
Global expansion	Emerging markets’ uptake

Key Takeaways

• Lipitor's revenue plummeted post-2011 due to patent expiry but retains residual market presence.
• The global statin market is projected to grow modestly (~4.5% CAGR), driven by increased cardiovascular disease burden.
• Competitive landscape has shifted towards higher-potency statins, PCSK9 inhibitors, and biosimilars.
• Strategic opportunities include indication expansion, formulation innovation, and geographic growth.
• Investment prospects hinge on effectively managing patent cliffs, navigating regulatory environments, and capturing emerging markets.

FAQs

1. Will Lipitor regain significant market share in the future?
Unlikely, given the dominance of generics and alternative therapies; however, niche or specialized indications could sustain residual revenues.

2. How does the entry of biosimilars impact Lipitor’s market?
While biosimilars primarily target biologics, their increasing presence pressures generic small-molecule statin pricing and market share, indirectly affecting Lipitor.

3. What are the regulatory hurdles for repositioning Lipitor or developing new formulations?
They involve proving bioequivalence, securing new patent protections or exclusivities, and navigating complex approval pathways in various jurisdictions.

4. Which markets offer the most growth potential for Lipitor derivatives?
Emerging markets, including Asia-Pacific and Latin America, show significant growth due to rising CVD prevalence and expanding healthcare coverage.

5. How does Lipitor compare to newer lipid-lowering agents like PCSK9 inhibitors in cost-effectiveness?
Lipitor remains highly cost-effective, especially post-generic, whereas PCSK9 inhibitors, although potent, are considerably more expensive and reserved for high-risk groups.

References

1. IMS Health, "Global Cardiovascular Market Analysis," 2022.
2. U.S. FDA, "Lipitor (Atorvastatin) Approval History," 1996–2011.
3. Pfizer Investor Relations, "Lipitor Market Share and Revenue Data," 2011–2022.
4. MarketsandMarkets, "Statin Market by Type and Region," 2022.
5. European Medicines Agency, "Biosimilar Approvals," 2022.

---

Note: This comprehensive review is curated for business professionals requiring an in-depth understanding of Lipitor’s investment landscape, highlighting market trajectories, competitive positioning, and future prospects grounded in recent data and policy environments.